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1. Introduction 
Diabetes mellitus (DM) is a group of 
diseases characterized by high levels of blood 
glucose resulting from defects in insulin 
production, insulin action, or both (1). The term 
diabetes mellitus describes a metabolic disorder 
of multiple aetiology characterized by chronic 
hyperglycaemia with disturbances of 
carbohydrate, fat and protein metabolism 
resulting from defects in insulin secretion, 
insulin action, or both (2).  
Several pathogenic processes are involved 
in the development of diabetes. These range 
from autoimmune destruction of the β-cells of 
the pancreas with consequent insulin deficiency 
to abnormalities that result in resistance to 
insulin action. The effects of diabetes mellitus 
include long–term damage, dysfunction and 
failure of various organs. Diabetes mellitus may 
present with characteristic symptoms such as 
thirst, polyuria, blurring of vision, and weight 
loss. In its most severe forms, ketoacidosis or a 
non-ketotic hyperosmolar state may develop 
and lead to stupor, coma and, in absence of 
effective treatment, death (3). Often symptoms 
are not severe, or may be absent, and 
consequently hyperglycaemia sufficient to 
cause pathological and functional changes may 
be present for a long time before the diagnosis 
is made (4).  
Symptoms of marked hyperglycemia 
include polyuria, polydipsia, weight loss, 
sometimes with polyphagia, and blurred vision. 
Impairment of growth and susceptibility to 
certain infections may also accompany chronic 
hyperglycemia. Acute, life-threatening 
consequences of uncontrolled diabetes are 
hyperglycemia with ketoacidosis or the 
nonketotic hyperosmolar syndrome. The long–
term effects of diabetes mellitus include 
progressive development of the specific 
complications of retinopathy with potential 
blindness, nephropathy that may lead to renal 
failure, and/or neuropathy with risk of foot 
ulcers, amputation, Charcot joints, and features 
of autonomic dysfunction, including sexual 
dysfunction (5). People with diabetes are at 
increased risk of cardiovascular, peripheral 
vascular and cerebrovascular disease. 
Classification of diabetes mellitus is based on 
its aetiology and clinical presentation. As such, 
there are four types or classes of diabetes 
mellitus viz; type 1 diabetes, type 2 diabetes, 
gestational diabetes, and other specific types 
(6). 
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Assigning a type of diabetes to an individual 
often depends on the circumstances present at 
the time of diagnosis, and many diabetic 
individuals do not easily fit into a single class. 
For example, a person with gestational diabetes 
mellitus (GDM) may continue to be 
hyperglycemic after delivery and may be 
determined to have, in fact, type 2 diabetes. It is 
currently a common and serious health concern 
globally. According to WHO, (1994), this 
problem has been aggravated by rapid cultural 
and social dynamics, ageing populations, 
increasing urbanization, dietary changes, 
reduced physical activity and other unhealthy 
lifestyle and behavioral patterns. Diabetes 
mellitus and lesser forms of glucose intolerance, 
particularly impaired glucose tolerance, can 
now be found in almost every population in the 
world and epidemiological evidence suggests 
that, without effective prevention and control 
programmes, diabetes will likely continue to 
increase globally (7). 
This estimate is expected to increase to 
about 438 million, by 2030. Further, by 2030, 
the number of people with IGT is projected to 
increase to 472 million, or 8.4% of the adult 
population. The debilitating effects of diabetes 
mellitus include various organ failures, 
progressive metabolic complications such as 
retinopathy, nephropathy, and/or neuropathy 
(8). Diabetics are accompanied by risk of 
cardiovascular, peripheral vascular and 
cerebrovascular diseases (9). 
2. Materials and methods 
The methodology of the research includes 
the research design, description of the setting, 
population, sample, sampling technique and 
development of the tool, procedure for data 
collection and plan for data analysis. Efforts for 
improved criteria for diagnosis & classification 
started a decade before Von Mering & 
Minkowski's work. Lancereaux divided diabetes 
into the 'lean' & 'fat' category. During pre & 
post insulin eras, various adjectives were used 
to classify & describe diabetes. A major 
requirement for epidemiological and clinical 
research and for the clinical management of 
diabetes is an appropriate system of 
classification that provides a framework within 
which to identify and differentiate it's various 
forms and stages. 
Research Design 
A. Primary Data 
1] Insulin dependent diabetes mellitus (IDDM, 
Type 1) 
2] Non-insulin dependent diabetes mellitus 
(NIDDM, Type 2)  
a) Non obese NIDDM (Type 1 in evolution) 
b) Obese NIDDM 
c) Maturity onset diabetes of the young (MODY) 
B. Secondary:  
1] Pancreatic disease e.g- chronic pancreatitis in 
alcholics. 
2] Hormonal abnormalities.e.g. 
pheochromocytoma, Cushing's syndrome. 
3] Drug or chemical induced. 
4] Insulin receptor abnormalities. 
5] Genetic syndromes e.g. lipodystrophies. 
6] Others include poorly or ill-defined types 
which do not fit into any of the above. 
3. Result and Discussion 
Diabetes may be diagnosed based on plasma 
glucose criteria, either the fasting plasma 
glucose (FPG) or the 2-h plasma glucose (2-h 
PG) value after a 75-g oral glucose tolerance 
test (OGTT) or A1C criteria. (Table 4.1) FPG, 
2-h PG after 75-g OGTT, and A1C are equally 
appropriate for diagnostic testing. It should be 
noted that the tests do not necessarily detect 
diabetes in the same individuals. The efficacy of 
interventions for primary prevention of type2 
diabetes has primarily been demonstrated 
among individuals with impaired glucose 
tolerance (IGT), not for individuals with 
isolated impaired fasting glucose (IFG) or for 
those with prediabetes defined by A1C criteria. 
The same tests may be used to screen for and 
diagnose diabetes and to detect individuals with 
prediabetes. Diabetes may be identified 
anywhere along the spectrum of clinical 
scenarios: in seemingly low-risk individuals 
who happen to have glucose testing, in 
individuals tested based on diabetes risk 
assessment, and in symptomatic patients. 
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Table 1 Staging of type 1 diabetes 













No IGT or IFG 
Multiple autoantibodies 
Dysglycemia: IFG and/or IGT 
FPG 100–125 mg/dL (5.6–6.9 
mmol/L) 2-h PG 140–199 mg/dL 
(7.8–11.0 mmol/L) A1C 5.7–
6.4% (39–47 mmol/mol) or 
$10% increase in A1C 
Clinical symptoms 
Diabetes by standard criteria 
 
Fasting and 2-Hour Plasma Glucose 
The FPG and 2-h PG may be used to 
diagnose diabetes (Table 4.2). The concordance 
between the FPG and 2-h PG tests is imperfect, 
as is the concordance between A1C and either 
glucose-based test. Numerous studies have 
confirmed that, compared with FPG and A1C cut 
points, the 2-h PG value diagnoses more people 
with diabetes. 
Table 2 Criteria for the diagnosis of diabetes 
FPG >126 mg/dL (7.0 mmol/L). Fasting is defined as no caloric intake for at least 8 h 
OR 
2-h PG>200 mg/dL (11.1 mmol/L) during an OGTT. The test should be performed as 
described by the WHO, using a glucose load containing the equivalent of 75 g anhydrous 
glucose dissolved in water 
OR 
A1C > 6.5% (48 mmol/mol). The test should be performed in a laboratory using a method that 
is NGSP certified and standardized to the DCCT assay 
OR 
In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma 
glucose > 200 mg/dL (11.1 mmol/L). 
 
Confirming the diagnosis 
Unless there is a clear clinical diagnosis (e.g., 
patient in a hyperglycemic crisis or with classic 
symptoms of hyperglycemia and a random 
plasma glucose > 200 mg/dL [11.1 mmol/L]), a 
second test is required for confirmation. It is 
recommended that the same test be repeated 
without delay using a new blood sample for 
confirmation because there will be a greater 
likelihood of concurrence. For example, if the 
A1C is 7.0% (53 mmol/mol) and a repeat result 
is 6.8% (51 mmol/mol), the diagnosis of diabetes 
is confirmed. If two different tests (such as A1C 
and FPG) are both above the diagnostic 
threshold, this also confirms the diagnosis. On 
the other hand, if a patient has discordant results 
from two different tests, then the test result that 
is above the diagnostic cut point should be 
repeated. The diagnosis is made on the basis of 
the confirmed test. For example, if a patient 
meets the diabetes criterion of the A1C (two 
results $6.5% [48 mmol/mol]) but not FPG (< 
126 mg/dL [7.0 mmol/L]), that person should 
nevertheless be considered to have diabetes. 
Since all the tests have preanalytic and 
analytic variability, it is possible that an 
abnormal result (i.e., above the diagnostic 
threshold), when repeated, will produce a value 
below the diagnostic cut point. This scenario is 
likely for FPG and 2-h PG if the glucose samples 
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remain at room temperature and are not 
centrifuged promptly. Because of the potential 
for preanalytic variability, it is critical that 
samples for plasma glucose be spun and 
separated immediately after they are drawn. If 
patients have test results near the margins of the 
diagnostic threshold, the health care professional 
should follow the patient closely and repeat the 
test in 3–6 months. 
Criteria for diagnosis of Diabetes Mellitus 
In 1997, the first Expert Committee on the 
Diagnosis and Classification of Diabetes 
Mellitus revised the diagnostic criteria, using the 
observed association between FPG levels and 
presence of retinopathy as the key factor with 
which to identify threshold glucose level. 
Table 3 Criteria for testing for diabetes or prediabetes in asymptomatic adults 
1. Testing should be considered in overweight or obese (BMI >25 kg/m2 or > 23 kg/m2 
adults who have one or more of the following risk factors: 
A1C > 5.7% (39 mmol/mol), IGT, or IFG on previous testing 
First-degree relative with diabetes 
High-risk race/ethnicity (e.g., African American, Latino, Native American, Asian American, 
Pacific Islander 
Women who were diagnosed with GDM 
History of CVD 
Hypertension ($140/90 mmHg or on therapy for hypertension) 
HDL cholesterol level <35 mg/dL (0.90 mmol/L) and/or a triglyceride level >250 mg/dL (2.82 
mmol/L) 
women with polycystic ovary syndrome 
physical inactivity 
Other clinical conditions associated with insulin resistance (e.g., severe obesity, acanthosis 
nigricans). 
For all patients, testing should begin at age 45 years. 
If results are normal, testing should be repeated at a minimum of 3-year intervals, with 
consideration of more frequent testing depending on initial results (e.g., those with prediabetes 
should be tested yearly) and risk status 
 
Genetic defects in insulin action 
There are unusual causes of diabetes that 
result from genetically determined abnormalities 
of insulin action. The metabolic abnormalities 
associated with mutations of the insulin receptor 
may range from hyperinsulinemia and modest 
hyperglycemia to severe diabetes. Some 
individuals with these mutations may have 
acanthosis nigricans. Women may be virilized 
and have enlarged, cystic ovaries. In the past, 
this syndrome was termed type A insulin 
resistance.  
Testing for gestational diabetes 
Previous recommendations included 
screening for GDM performed in all pregnancies. 
However, there are certain factors that place 
women at lower risk for the development of 
glucose intolerance during pregnancy, and it is 
likely not cost-effective to screen such patients. 
Pregnant women who fulfill all of these criteria 
need not be screened for GDM. 
Monogenic Diabetes Syndromes 
Monogenic defects that cause b-cell 
dysfunction, such as neonatal diabetes and 
MODY, represent a small fraction of patients 
with diabetes (<5%). 
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GCK-MODY: stable, nonprogressive elevated fasting 
blood glucose; typically does not require treatment; 
microvascular complications are rare; small rise in 2-h 
PG level on OGTT(<54 mg/dL [3mmol/L]) 
HNF1A-MODY: progressive insulin secretory defect 
with presentation in adolescence or early adulthood; 
lowered renal threshold for glucosuria; large rise in 2-
h PG level on OGTT (>90 mg/dL [5 mmol/L]); 
sensitive to sulfonylureas 
HNF4A-MODY: progressive insulin secretory defect 
with presentation in adolescence or early adulthood; 
may have large birth weight and transient neonatal 
hypoglycemia; sensitive to sulfonylureas 
HNF1B-MODY: developmental renal disease 
(typically cystic); genitourinary abnormalities; atrophy 













Permanent or transient: IUGR; possible 
developmental delay and seizures; responsive to 
sulfonylureas 
Permanent: IUGR; insulin requiring 
Transient or permanent: IUGR; rarely developmental 
delay; responsive to sulfonylureas 
 
Drug- or chemical-induced diabetes 
Many drugs can impair insulin secretion. 
These drugs may not cause diabetes by 
themselves, but they may precipitate diabetes in 
individuals with insulin resistance. In such cases, 
the classification is unclear because the sequence 
or relative importance of β-cell dysfunction and 
insulin resistance is unknown. 
Neonatal Diabetes 
Diabetes occurring under 6 months of age is 
termed “neonatal” or “congenital” diabetes, and 
about 80–85% of cases can be found to have an 
underlying monogenic cause. Neonatal diabetes 
occurs much less often after 6 months of age, 
whereas autoimmune type 1 diabetes rarely 
occurs before 6 months of age. Neonatal diabetes 
can either be transient or permanent. Transient 
diabetes is most often due to over expression of 
genes on chromosome 6q24, is recurrent in about 
half of cases, and may be treatable with 
medications other than insulin. Permanent 
neonatal diabetes is most commonly due to 
autosomal dominant mutations in the genes 
encoding the Kir6.2 subunit (KCNJ11) and 
SUR1 subunit (ABCC8) of the b-cell KATP 
channel. Correct diagnosis has critical 
implications because most patients with KATP-
related neonatal diabetes will exhibit improved 
glycemic control when treated with high-dose 
oral sulfonylureas instead of insulin. Insulin gene 
(INS) mutations are the second most common 
cause of permanent neonatal diabetes, and, while 
treatment presently is intensive insulin 
management, there are important genetic 
considerations as most of the mutations that 
cause diabetes are dominantly inherited. 
Maturity-onset diabetes of the young 
MODY is frequently characterized by onset 
of hyperglycemia at an early age (classically 
before age 25 years, although diagnosis may 
occur at older ages). MODY is characterized by 
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impaired insulin secretion with minimal or no 
defects in insulin action (in the absence of 
coexistent obesity). It is inherited in an 
autosomal dominant pattern with abnormalities 
in at least 13 genes on different chromosomes 
identified to date. The most commonly reported 
forms are GCKMODY (MODY2), HNF1A-
MODY (MODY3), and HNF4A-MODY 
(MODY1). Clinically, patients with GCK-
MODY exhibit mild, stable, fasting 
hyperglycemia and do not require 
antihyperglycemic therapy except sometimes 
during pregnancy. Patients with HNF1A- or 
HNF4A-MODY usually respond well to low 
doses of sulfonylureas, which are considered 
first-line therapy. Mutations or deletions in 
HNF1B are associated with renal cysts and 
uterine malformations (renal cysts and diabetes 
[RCAD] syndrome). Other extremely rare forms 
of MODY have been reported to involve other 
transcription factor genes including PDX1 
(IPF1) and NEUROD1. 
Uncommon forms of immune-mediated 
diabetes 
In this category, there are two known 
conditions, and others are likely to occur. The 
stiff-man syndrome is an autoimmune disorder 
of the central nervous system characterized by 
stiffness of the axial muscles with painful 
spasms. Patients usually have high titers of the 
GAD autoantibodies, and approximately one-
third will develop diabetes. 
4. Conclusion 
The classification of DM reflects 
heterogeneous nature of the condition and 
diverse clinical presentations. Patients with 
diabetic disease are characterized by insulin 
resistance with growing clinical and 
experimental evidence indicating that insulin 
resistance is an important and crucial player in 
the patho-physiology of diabetic disease. 
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